Davide Prandi

Davide Prandi

Auto-generated profile, based on publicly available information

Davide Prandi

Software Engineering Unit Fondazione Bruno Kessler Trento Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Cell
Verified
Journal Article
Closed access
AAAdam Abeshouse
Adam Abeshouse
JAJaeil Ahn
Jaeil Ahn
RARehan Akbani
Rehan Akbani
AAAdrian Ally
Adrian Ally
SASamirkumar Amin
Samirkumar Amin
EZErik Zmuda
Erik Zmuda

8 February 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HBHimisha Beltran
Himisha Beltran
DPDavide Prandi
Davide Prandi
JMJuan Miguel Mosquera
Juan Miguel Mosquera
MBMatteo Benelli
Matteo Benelli
LPLoredana Puca
Loredana Puca
FDFrancesca Demichelis
Francesca Demichelis
Genome-wide DNA methylation analysis of metastatic biopsies from patients with castration-resistant prostate cancer reveals marked epigenetic differences between samples with adenocarcinoma and neuroendocrine histologies. An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to absent AR expression and often have neuroendocrine features. The etiology and molecular basis for this 'alternative' treatment-resistant cell state remain incompletely understood. Here, by analyzing whole-exome sequencing data of metastatic biopsies from patients, we observed substantial genomic overlap between castration-resistant tumors that were histologically characterized as prostate adenocarcinomas (CRPC-Adeno) and neuroendocrine prostate cancer (CRPC-NE); analysis of biopsy samples from the same individuals over time points to a model most consistent with divergent clonal evolution. Genome-wide DNA methylation analysis revealed marked epigenetic differences between CRPC-NE tumors and CRPC-Adeno, and also designated samples of CRPC-Adeno with clinical features of AR independence as CRPC-NE, suggesting that epigenetic modifiers may play a role in the induction and/or maintenance of this treatment-resistant state. This study supports the emergence of an alternative, 'AR-indifferent' cell state through divergent clonal evolution as a mechanism of treatment resistance in advanced prostate cancer.

6 May 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WAWassim Abida
Wassim Abida
JCJoanna Cyrta
Joanna Cyrta
GHGlenn Heller
Glenn Heller
DPDavide Prandi
Davide Prandi
JAJoshua Armenia
Joshua Armenia
CSCharles L. Sawyers
Charles L. Sawyers
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, we report comprehensive genomic and transcriptomic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) linked with longitudinal clinical outcomes, integrating findings from whole-exome, transcriptome, and histologic analysis. For 128 patients treated with a first-line next-generation androgen receptor signaling inhibitor (ARSI; abiraterone or enzalutamide), we examined the association of 18 recurrent DNA- and RNA-based genomic alterations, including androgen receptor ( AR ) variant expression, AR transcriptional output, and neuroendocrine expression signatures, with clinical outcomes. Of these, only RB1 alteration was significantly associated with poor survival, whereas alterations in RB1 , AR , and TP53 were associated with shorter time on treatment with an ARSI. This large analysis integrating mCRPC genomics with histology and clinical outcomes identifies RB1 genomic alteration as a potent predictor of poor outcome, and is a community resource for further interrogation of clinical and molecular associations.

1 April 2013 in Cell
Verified
Journal Article
Closed access
SBSylvan C. Baca
Sylvan C. Baca
DPDavide Prandi
Davide Prandi
MLMichael S. Lawrence
Michael S. Lawrence
JMJuan Miguel Mosquera
Juan Miguel Mosquera
ARAlessandro Romanel
Alessandro Romanel
LGLevi A. Garraway
Levi A. Garraway

6 January 2017 in Science
Verified
Journal Article
Closed access
PDF file
PMPing Mu
Ping Mu
ZZZeda Zhang
Zeda Zhang
MBMatteo Benelli
Matteo Benelli
WKWouter R. Karthaus
Wouter R. Karthaus
EHElizabeth Hoover
Elizabeth Hoover
CSCharles L. Sawyers
Charles L. Sawyers
Evading cancer drugs by identity fraud: Prostate cancer growth is fueled by male hormones called androgens. Drugs targeting the androgen receptor (AR) are initially efficacious, but most tumors eventually become resistant (see the Perspective by Kelly and Balk). Mu et al. found that prostate cancer cells escaped the effects of androgen deprivation therapy through a change in lineage identity. Functional loss of the tumor suppressors TP53 and RB1 promoted a shift from AR-dependent luminal epithelial cells to AR-independent basal-like cells. In related work, Ku et al. found that prostate cancer metastasis, lineage switching, and drug resistance were driven by the combined loss of the same tumor suppressors and were accompanied by increased expression of the epigenetic regulator Ezh2. Ezh2 inhibitors reversed the lineage switch and restored sensitivity to androgen deprivation therapy in experimental models. Science , this issue p. 84 , p. 78 ; see also p. 29

30 April 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
CPChantal Pauli
Chantal Pauli
BHBenjamin D. Hopkins
Benjamin D. Hopkins
DPDavide Prandi
Davide Prandi
RSReid Shaw
Reid Shaw
TFTarcisio Fedrizzi
Tarcisio Fedrizzi
MRMark A. Rubin
Mark A. Rubin
Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures and 19 patient-derived xenograft (PDX) models have been established from the 769 patients enrolled in an Institutional Review Board–approved clinical trial. Because genomics alone was insufficient to identify therapeutic options for the majority of patients with advanced disease, we used high-throughput drug screening to discover effective treatment strategies. Analysis of tumor-derived cells from four cases, two uterine malignancies and two colon cancers, identified effective drugs and drug combinations that were subsequently validated using 3-D cultures and PDX models. This platform thereby promotes the discovery of novel therapeutic approaches that can be assessed in clinical trials and provides personalized therapeutic options for individual patients where standard clinical options have been exhausted. Significance: Integration of genomic data with drug screening from personalized in vitro and in vivo cancer models guides precision cancer care and fuels next-generation research. Cancer Discov; 7(5); 462–77. ©2017 AACR. See related commentary by Picco and Garnett, p. 456. This article is highlighted in the In This Issue feature, p. 443